MedMira Inc., a Canadian pharma major specialising in fast diagnostics, is based in Halifax, Nova Scotia, Canada. It specialises in rapid vertical flow technology, providing fast disease diagnosis for HIV, syphilis, hepatitis, and SARS-CoV-2 to hospitals, labs, clinics, and individuals in just three simple steps. Health Canada has approved MedMira Inc.'s Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) for use at Points of Care (POC). This milestone is a critical step towards improving quick HIV detection in Canada. The test has a sensitivity of 99.64% and a specificity of 99.71 percent, guaranteeing that healthcare workers receive timely and reliable findings in any medical context. 

The Reveal HIV test yields a rapid response by identifying HIV-1/2 antibodies in a small finger-prick blood sample. Unlike traditional HIV testing, which can take days or weeks, this test produces results in less than a minute. Another advantage is that the results do not fade, which eliminates the possibility of misinterpretation. 

Furthermore, the test does not require any particular storage conditions, making it suitable for a variety of healthcare settings, including distant and underserved regions. Healthcare providers can confirm appropriate test execution thanks to MedMira's unique Rapid Vertical Flow Technology, which offers built-in reagent and procedural control. 

"Our Reveal HIV test is one of the fastest and most reliable solutions for HIV detection," stated Hermes Chan, CEO of MedMira. "As HIV infections continue to climb in Canada, healthcare practitioners require tests that are not only accurate but also easy, cost-effective, and easily accessible. Whether in underserved remote areas or congested major centres, our test yields rapid and actionable results. 

MedMira's collaboration with organisations such as REACH Nexus intends to increase HIV screening across Canada, thereby boosting public health initiatives focusing on early detection and treatment. 

The Public Health Agency of Canada recently reported a 35% increase in new HIV infections between 2022 and 2023. The issue is especially severe in Manitoba, where cases have increased by more than 40%, and Saskatchewan, which has an HIV rate of 19.4 per 100,000 individuals, more than three times the national average. 

These frightening results emphasise the critical need for faster and more accessible HIV screening, emphasising the need for rapid diagnostic options such as MedMira's Reveal HIV test. 

This clearance follows the December 24, 2024, approval of MedMira's Multiplo TP/HIV fast test, which detects both syphilis and HIV. The company intends to provide a wide range of diagnostic solutions to meet various healthcare demands. MedMira also expects Health Canada to approve its Reveal TP test (for detecting syphilis) in the coming weeks.